ClinicaliQ Trial Snapshot
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT06276491.
- Drug being tested: XmAb541, an investigational immunotherapy agent, is undergoing Phase 1 evaluation to establish safety, tolerability, and optimal dosing in patients with advanced solid tumors.
- Patient eligibility: The trial recruits adults with advanced/metastatic solid tumors who have exhausted standard treatment options or for whom conventional therapies are unsuitable, typically requiring adequate organ function and performance status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Eligibility Snapshot
- Key Inclusion Criteria: * Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment * Adequate Eastern Cooperative Oncology Group performance status * Life expectancy ≥ 3 months * Adequate liver, kidney, and bone marrow function Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.